Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
West China Hospital
West China Hospital
National Institutes of Health Clinical Center (CC)
Ipsen
Centre Hospitalier Universitaire Dijon
Methodist Health System
Novartis
Huazhong University of Science and Technology
University of California, Davis
Memorial Sloan Kettering Cancer Center
National Institute of Cardiology, Warsaw, Poland
Children's Oncology Group
Assistance Publique - Hôpitaux de Paris
University of Nebraska
IRCCS San Raffaele
First Affiliated Hospital of Zhejiang University
University Hospital, Strasbourg, France
Advanced Accelerator Applications
University of Iowa
Hospices Civils de Lyon
Wren Laboratories LLC
National Institutes of Health Clinical Center (CC)
Massive Bio, Inc.
Cook Group Incorporated
University Hospital, Brest
British Columbia Cancer Agency
Hospices Civils de Lyon
Tongji Hospital
IRCCS San Raffaele
Nanjing First Hospital, Nanjing Medical University
University of Roma La Sapienza
Grupo Espanol de Tumores Neuroendocrinos
Western Sydney Local Health District
First Affiliated Hospital, Sun Yat-Sen University
Jagiellonian University
Latin American Cooperative Oncology Group
Central Hospital, Nancy, France
University of Pennsylvania
University Hospital, Basel, Switzerland
Asan Medical Center
European Institute of Oncology
Istituto Clinico Humanitas
Taproot Health
Ipsen
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fujian Maternity and Child Health Hospital
Universidad Nacional Autonoma de Mexico
TerSera Therapeutics LLC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
University Medical Center Groningen
University Medical Center Groningen